Adefovir dipivoxil
- Generic Name
- Adefovir dipivoxil
- Brand Names
- Hepsera
- Drug Type
- Small Molecule
- Chemical Formula
- C20H32N5O8P
- CAS Number
- 142340-99-6
- Unique Ingredient Identifier
- U6Q8Z01514
- Background
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
- Indication
Indicated for the treatment of chronic hepatitis B in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease; this is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.
- Associated Conditions
- Chronic Hepatitis B Infection
Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
- Conditions
- Hepatitis B
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-03-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT00158704
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Novartis
- Registration Number
- NCT00115245
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
- Conditions
- Hepatitis CHepatitis BHIV Infections
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00042393
A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV
- Conditions
- HIV InfectionsHepatitis B
- First Posted Date
- 2002-04-09
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00033163
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Univ. of Cincinnati CRS, Cincinnati, Ohio, United States
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 475
- Registration Number
- NCT00000912
- Locations
- 🇺🇸
USC Univ Hosp & Ambulatory Hlth Care Ctr / USC Med Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
- Conditions
- Cytomegalovirus InfectionsHIV Infections
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-10-01
- Target Recruit Count
- 505
- Registration Number
- NCT00001082
- Locations
- 🇺🇸
North Jersey Community Research Initiative, Newark, New Jersey, United States
🇺🇸Community Consortium / UCSF, San Francisco, California, United States
🇺🇸Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 440
- Registration Number
- NCT00000885
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States
🇺🇸Boston Med Ctr, Boston, Massachusetts, United States
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT00001087
- Locations
- 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002234
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
🇺🇸Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.